Hancock Jill A, Palmer Glen A
Department of Pathology and Laboratory, St. Cloud VA Health Care System, St. Cloud, MN.
Research Program Coordinator, St. Cloud VA Health Care System, St. Cloud, MN.
Lab Med. 2019 Jul 16;50(3):263-267. doi: 10.1093/labmed/lmy075.
Single-vial fecal immunochemical testing (FIT) is an accepted method of colorectal cancer (CRC) screening. The available 3-vial FIT data set allows for comparison of colonoscopy results using various screening methods.
To determine the optimal number of vials for a strong FIT-screening program by examining whether using only a single vial impacts the use of colonoscopy for CRC screening.
Patients were given 3-vial FIT collection kits that were processed with a positive hemoglobin cut-off detection level of 100 ng per mL. If FIT results were positive, colonoscopy testing was performed using standard practices.
Detection of CRC and precursor adenoma was examined in 932 patients, with a positive colonoscopy sensitivity of 56.2% and 3.0% CRC detection after 3-vial FIT; after single-vial screening, those values were 60.9% and 4.7%, respectively.
Prescreening patients with FIT testing before colonoscopy allows colonoscopy testing to be targeted to higher-risk patients. Implementing use of only a single vial from the 3-vial FIT screening kit would reduce the colonoscopy reflex rate, colonoscopy complication numbers, facility costs, and patient distress by more than 40%, compared with 3-vial screening.
单瓶粪便免疫化学检测(FIT)是一种公认的结直肠癌(CRC)筛查方法。现有的三瓶FIT数据集允许使用各种筛查方法比较结肠镜检查结果。
通过检查仅使用单瓶是否会影响结肠镜检查在CRC筛查中的应用,确定强有力的FIT筛查计划的最佳瓶数。
给患者提供三瓶FIT采集试剂盒,以每毫升100纳克的阳性血红蛋白截断检测水平进行处理。如果FIT结果为阳性,则按照标准操作进行结肠镜检查。
对932例患者进行了CRC和癌前腺瘤的检测,三瓶FIT检测后结肠镜检查的阳性敏感性为56.2%,CRC检测率为3.0%;单瓶筛查后,这些值分别为60.9%和4.7%。
在结肠镜检查前对患者进行FIT检测预筛查,可使结肠镜检查针对高危患者。与三瓶筛查相比,仅使用三瓶FIT筛查试剂盒中的单瓶进行检测,将使结肠镜检查的回检率、结肠镜检查并发症数量、设备成本和患者痛苦减少40%以上。